Human IGG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech Европска Унија - Дански - EMA (European Medicines Agency)

human igg1 monoclonal antibody specific for human interleukin-1 alpha xbiotech

xbiotech germany gmbh - humant igg1 monoklonalt antistof specifikt for human interleukin-1 alfa - kolorektale neoplasmer - antineoplastiske midler - behandling af metastatisk kolorektal cancer.

Dengvaxia Европска Унија - Дански - EMA (European Medicines Agency)

dengvaxia

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vacciner - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 og 4. brug af dengvaxia bør være i overensstemmelse med de officielle anbefalinger.

Shingrix Европска Унија - Дански - EMA (European Medicines Agency)

shingrix

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - vacciner - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. brug af shingrix bør være i overensstemmelse med de officielle anbefalinger.

Pumarix Европска Унија - Дански - EMA (European Medicines Agency)

pumarix

glaxosmithkline biologicals s.a.  - pandemic influenza vaccine (h5n1) (split virion, inaktiveret, adjuvanted) - influenza, human; immunization; disease outbreaks - vacciner - prophylax af influenza i en officielt erklæret pandemisk situation. pandemic influenza vaccine bør anvendes i overensstemmelse med officielle retningslinjer.

Jcovden (previously COVID-19 Vaccine Janssen) Европска Унија - Дански - EMA (European Medicines Agency)

jcovden (previously covid-19 vaccine janssen)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vacciner - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.

Human Albumin "CSL Behring" 20 % infusionsvæske, opløsning Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

human albumin "csl behring" 20 % infusionsvæske, opløsning

csl behring gmbh - albumin, human - infusionsvæske, opløsning - 20 %

Human Albumin "CSL Behring" 5 % infusionsvæske, opløsning Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

human albumin "csl behring" 5 % infusionsvæske, opløsning

csl behring gmbh - albumin, human - infusionsvæske, opløsning - 5 %

Trumenba Европска Унија - Дански - EMA (European Medicines Agency)

trumenba

pfizer europe ma eeig - neisseria meningitidis serogruppe b fhbp (rekombinant lipideret fhbp (faktor h bindende protein)) subfamilie a; neisseria meningitidis serogruppe b fhbp (rekombinant lipideret fhbp (faktor h bindende protein)) subfamilie b - meningitis, meningokok - bacterial vaccines, meningococcal vaccines - trumenba er indiceret til aktiv immunisering af individer 10 år og ældre for at forhindre invasiv meningokok sygdom forårsaget af neisseria meningitidis serogruppe b. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.

Arexvy Европска Унија - Дански - EMA (European Medicines Agency)

arexvy

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - respiratoriske syncytiale virusinfektioner - vacciner - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.

Menveo Европска Унија - Дански - EMA (European Medicines Agency)

menveo

gsk vaccines s.r.l. - meningokokgruppe a, c, w-135 og y-konjugatvaccine - immunization; meningitis, meningococcal - bakterievacciner - vialsmenveo er indiceret til aktiv immunisering af børn (fra to år), unge og voksne risiko for eksponering for neisseria meningitidis gruppe a, c, w135 og y, for at forhindre, at invasive sygdom. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.